The amylin hormone
Every time your pancreas releases insulin after a meal, it releases a second hormone alongside it: amylin.
The forgotten twin of insulin
Every time your pancreas releases insulin after a meal, it releases a second hormone alongside it: amylin. For decades amylin was overshadowed by insulin, but it turns out to be a key brake on appetite and a regulator of how fast food leaves the stomach.
This unit covers the biology cagrilintide is built on: what amylin does, the unusual receptor it uses, and the "amyloid" problem that made copying it surprisingly hard.
Key terms
Released with insulin
Amylin is co-secreted with insulin from pancreatic beta cells after a meal, at roughly a 1-to-100 ratio of amylin to insulin. While insulin tells the body's tissues to take up and store nutrients, amylin sends a parallel message to the brain: the meal is arriving, start feeling full. The two hormones are partners, released together and acting on different targets.
This pairing explains why amylin became an obesity target. It is a built-in, meal-triggered appetite brake that the body already uses. A drug that safely amplifies amylin is not introducing a foreign mechanism; it is turning up a natural post-meal signal that helps end eating, which is exactly what cagrilintide is designed to do.
AdvancedWhy amylin was overlooked for so long
Amylin was identified in 1986, decades after insulin, and its co-secretion made it easy to attribute its effects to insulin. Two independent groups found it as the major component of the pancreatic islet amyloid deposits long known as a hallmark of type 2 diabetes, a pathological role that initially overshadowed its normal physiology. Recognizing it as a legitimate satiety hormone, rather than just a disease byproduct, is what eventually made it a drug target.